[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Wu J, Crimmins JT, Monk KR, Williams JP, Fitzgerald ME, Tedesco S, Ratner N: Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma. Am J Pathol; 2006 May;168(5):1686-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma.
  • Benign peripheral nerve tumors called neurofibromas are a major source of morbidity for patients with neurofibromatosis type 1.
  • Later treatment was much less effective.
  • A birth to 2-week pulse of cetuximab blocked hEGFR phosphorylation and Schwann cell prolifera-tion in perinatal mutant nerve, so CNPase-hEGFR Schwann cell numbers correlate with the cetuximab effect.

  • Hazardous Substances Data Bank. CETUXIMAB .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Dermatol. 2003 Aug;12(4):412-7 [12930297.001]
  • [Cites] Neuron. 1999 Jun;23(2):273-83 [10399934.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1679-85 [15083203.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Mar;80(5):1337-41 [6298788.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1225-9 [3080222.001]
  • [Cites] Cell. 1990 Apr 20;61(2):203-12 [2158859.001]
  • [Cites] J Dermatol Sci. 1992 May;3(3):137-44 [1498092.001]
  • [Cites] J Clin Pathol. 1993 Jan;46(1):86-7 [8432898.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4322-8 [8364927.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Feb 15;198(3):827-34 [8117287.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Arch Dermatol Res. 1999 Jun;291(6):318-24 [10421057.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):1-6 [10469430.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):31-7 [10469434.001]
  • [Cites] J Invest Dermatol. 1999 Sep;113(3):398-402 [10469340.001]
  • [Cites] Cancer Gene Ther. 1999 Sep-Oct;6(5):423-7 [10505852.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):65-75 [15652750.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5589-605 [15897877.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2176-9 [10591653.001]
  • [Cites] Oncogene. 1999 Nov 11;18(47):6513-20 [10597254.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):904-14 [10673534.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):97-105 [11244508.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6550-65 [11426640.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2958-70 [11595683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]
  • [Cites] Head Neck. 2002 Feb;24(2):207-11 [11891951.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1253-64 [12006546.001]
  • [Cites] Neurology. 2002 May 28;58(10):1461-70 [12041525.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4507-13 [12154062.001]
  • [Cites] J Dermatol. 2002 Nov;29(11):713-7 [12484433.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):37-43; discussion 43 [12559183.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2213-24 [12612091.001]
  • [Cites] J Neurosci. 1994 Dec;14(12):7284-90 [7996175.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] J Neurosci. 1996 Oct 1;16(19):6107-18 [8815893.001]
  • [Cites] Pain. 1996 Aug;66(2-3):265-70 [8880849.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] J Pediatr. 1997 Nov;131(5):678-82 [9403645.001]
  • [Cites] Ann Med. 1997 Dec;29(6):531-4 [9562519.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1893-902 [9607929.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1311-8 [9815926.001]
  • [Cites] Biochem Pharmacol. 1999 Apr 15;57(8):917-25 [10086326.001]
  • [Cites] Brain. 1999 Mar;122 ( Pt 3):473-81 [10094256.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1236-43 [10096554.001]
  • [Cites] Nat Neurosci. 2003 Nov;6(11):1186-93 [14555954.001]
  • (PMID = 16651634.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS028840; United States / NCI NIH HHS / CA / T32 CA059268; United States / NINDS NIH HHS / NS / NS28840; United States / NCI NIH HHS / CA / T32-CA-59268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Chemotactic Factors; 0 / Fibroblast Growth Factor 9; 0 / Neurofibromin 1; 0 / Oncogene Proteins v-fos; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.4.- / 2',3'-Cyclic-Nucleotide Phosphodiesterases; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ PMC1606591
  •  go-up   go-down


2. Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A: EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol; 2009 Oct;22(10):1328-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.
  • To gain the insight into the involvement of signaling mediated by the mammalian target of rapamycin (mTOR) in the phenotype and biological profiles of tumors and tumor-like lesions of the bone and soft tissue, we analyzed the expression and phosphorylation (activation) of mTOR and its correlation with the status of upstream and downstream modulator proteins Akt, p70S6-kinase (S6K), and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), which we refer to collectively as mTOR cassette proteins.
  • Immunohistochemical analysis of 140 cases showed activation of Akt in 55% (61% in malignant and 27% in benign), and mTOR expression in 61% (66% in malignant and 39% in benign).
  • The preponderance of mTOR activation was found in tumors of peripheral nerve sheath (malignant peripheral nerve sheath tumor and schwannoma), skeletal muscle origin (rhabdomyosarcoma), and in those exhibiting epithelial nature (chordoma and synovial sarcoma).
  • We conclude that mTOR-mediated signaling proteins function not only in the proliferation of the tumor cells, but also in the differentiation and/or maintenance of morphological phenotypes in tumors of rhabdomyoblastic and nerve sheath cell origin.
  • Overall, these results suggest that inhibitors of mTOR cassette may be useful as novel components of combined chemotherapy for a defined subset of bone and soft tissue sarcomas.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Bone Neoplasms / enzymology. Phosphoproteins / analysis. Protein Kinases / analysis. Proto-Oncogene Proteins c-akt / analysis. Receptor, Epidermal Growth Factor / analysis. Ribosomal Protein S6 Kinases, 70-kDa / analysis. Signal Transduction. Soft Tissue Neoplasms / enzymology
  • [MeSH-minor] Cell Proliferation. Enzyme Activation. Humans. Immunoblotting. Immunohistochemistry. Mutation. Neoplasm Staging. Phosphorylation. Prognosis. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648884.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa
  •  go-up   go-down


3. Fiorella R, Di Nicola V, Fiorella ML, Spinelli DA, Coppola F, Luperto P, Madami L: Major salivary gland diseases. Multicentre study. Acta Otorhinolaryngol Ital; 2005 Jun;25(3):182-90
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign tumours account for 80% of case histories with a relationship 1:4 M/F, the most frequent being pleomorphic adenoma (57.3% of cases), followed by Warthin's tumour (32.4%), this rating not having been confirmed in case histories (8-10%) in the literature.
  • Diagnostic work-up included echotomography and fine-needle aspiration biopsy, less used imaging techniques were computed tomography, magnetic resonance imaging, Sialo-computed tomography.
  • Surgical treatment of benign tumours consisted, in 50% of cases, in superficial paroditectomy and in approximately 30% of total paroditectomy.
  • For malignant neoplasms, total parotidectomy was performed in approximately 50% of cases, while in the remaining 50% an almost equal rate of superficial parotidectomy was carried out and enlarged parotidectomy, with or without sacrificing the facial nerve, which was rebuilt in 60% of cases.
  • The lateral neck dissection most frequently carried out was of functional type in 54% and selective type in 46% with removal of levels I-III and II-IV in approximately 60% of cases.
  • Post-operative-complementary radiotherapy was very frequently performed instead of chemotherapy.
  • Oncological results obtained were compared with those reported in the literature: in fact for all benign neoplasms relapse ratings are about 5%, while for malignant tumours the worst prognosis was in squamous cell carcinoma with median of 37.7 on survival and metastasis rate of 16.5%.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas Radiol. 1999 Nov;43(4):520-2 [10901971.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1984-8 [11801983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):729-38 [11849796.001]
  • [Cites] Atlas Oral Maxillofac Surg Clin North Am. 1998 Mar;6(1):1-28 [11905347.001]
  • [Cites] J Laryngol Otol. 2002 Apr;116(4):285-7 [11945190.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2002 Apr;22(2):80-5 [12068476.001]
  • [Cites] J Laryngol Otol. 2002 May;116(5):359-62 [12080993.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2141-54 [12461331.001]
  • [Cites] Mund Kiefer Gesichtschir. 2003 Mar;7(2):94-101 [12664254.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):931-40 [12820326.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):57-62 [12842751.001]
  • [Cites] Laryngoscope. 2003 Aug;113(8):1299-303 [12897549.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):257-9 [12903612.001]
  • [Cites] J Laryngol Otol. 2003 Aug;117(8):624-9 [12956917.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):929-33 [12975263.001]
  • [Cites] World J Surg. 2003 Jul;27(7):863-7 [14509520.001]
  • [Cites] Head Neck. 2003 Nov;25(11):946-52 [14603455.001]
  • [Cites] Chir Ital. 2003 Nov-Dec;55(6):857-64 [14725226.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6 [12883818.001]
  • [Cites] Otolaryngol Pol. 2004;58(1):109-14 [15101269.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):113-27 [15062365.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2005 Feb;23(1):53-6 [15804023.001]
  • [ErratumIn] Acta Otorhinolaryngol Ital. 2005 Oct;25(5):following 337
  • (PMID = 16450775.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2639866
  •  go-up   go-down


Advertisement
4. Bakoyiannis KC, Georgopoulos SE, Klonaris CN, Tsekouras NS, Felekouras ES, Pikoulis EA, Griniatsos JE, Papalambros EL, Bastounis EA: Surgical treatment of carotid body tumors without embolization. Int Angiol; 2006 Mar;25(1):40-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of carotid body tumors without embolization.
  • AIM: Carotid body (CB) paragangliomas are rare neoplasms, usually benign.
  • This study deals with our 10-year experience in their surgical treatment and the evaluation of its effectiveness, without preoperative embolization.
  • No one of the patients underwent radiotherapy or chemotherapy.
  • Three patients had temporal cranial nerve lesions that resolved within 3 months.
  • CONCLUSIONS: Early surgical treatment is strongly recommended in almost all patients.
  • Preoperative embolism of the tumor does not need to be a routine procedure.
  • [MeSH-minor] Adult. Aged. Angioplasty. Female. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520723.001).
  • [ISSN] 0392-9590
  • [Journal-full-title] International angiology : a journal of the International Union of Angiology
  • [ISO-abbreviation] Int Angiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Lindegaard J, Heegaard S, Toft PB, Nysom K, Prause JU: Malignant transformation of a medulloepithelioma of the optic nerve. Orbit; 2010 Jun;29(3):161-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a medulloepithelioma of the optic nerve.
  • OBJECTIVE: To describe a case of malignant transformation of a medulloepithelioma of the optic nerve.
  • A benign non-teratoid medulloepithelioma of the optic nerve was surgically removed.
  • The boy was further treated with chemotherapy and radiotherapy and is still alive 36 months after primary surgery.
  • RESULTS: Medulloepithelioma of the optic nerve is extremely rare.
  • This is the first case described of a benign medulloepithelioma of the optic nerve, later transforming into a malignant tumour.
  • One third of patients with medulloepithelioma of the optic nerve have died from direct intracranial spread or metastasis to the central nervous system (CNS).
  • CONCLUSIONS: Medulloepithelioma of the optic nerve should be considered malignant despite morphology with tendency to spread to the CNS.
  • Furthermore; it should be considered as a differential diagnosis when observing a tumour of the optic nerve in a child.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Neoplasm Recurrence, Local / pathology. Neuroectodermal Tumors, Primitive / pathology. Optic Nerve Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Child, Preschool. Exophthalmos / diagnosis. Exophthalmos / etiology. Eye Enucleation / methods. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Orbit Evisceration / methods. Radiotherapy, Adjuvant. Risk Assessment. Stem Cell Transplantation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20497085.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Geenen JE: Benign pancreatic duct strictures: medical and endoscopic therapy. Can J Gastroenterol; 2000 Feb;14(2):127-9
Hazardous Substances Data Bank. PANCREATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign pancreatic duct strictures: medical and endoscopic therapy.
  • Pancreatic duct strictures usually reflect underlying pancreatic disease and are likely caused by one or more of the following: acute or chronic pancreatitis, benign or malignant pancreatic neoplasm, pseudocyst and trauma.
  • The characteristics of pancreatic strictures are identified, and medical and endoscopic therapy options are reviewed.
  • [MeSH-major] Analgesics / therapeutic use. Autonomic Nerve Block. Diet, Fat-Restricted. Endoscopy. Pancreatic Diseases / therapy. Pancreatic Ducts. Pancreatin / therapeutic use
  • [MeSH-minor] Celiac Plexus. Constriction, Pathologic / etiology. Constriction, Pathologic / therapy. Decision Making. Drug Therapy, Combination. Gastrointestinal Agents / therapeutic use. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10694285.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] CANADA
  • [Chemical-registry-number] 0 / Analgesics; 0 / Gastrointestinal Agents; 8049-47-6 / Pancreatin
  • [Number-of-references] 6
  •  go-up   go-down


7. Selesnick SH, Burt BM: Regional spread of nonneurogenic tumors to the skull base via the facial nerve. Otol Neurotol; 2003 Mar;24(2):326-33
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional spread of nonneurogenic tumors to the skull base via the facial nerve.
  • OBJECTIVE: This study examined the clinical and pathologic features of regional spread of nonneurogenic neoplastic disease to the intratemporal segments of the facial nerve.
  • PATIENTS: Six patients with neoplastic disease of nonneurogenic origin involving segments of the facial nerve within the temporal bone.
  • Five patients received adjuvant radiation, and two received adjuvant radiation and chemotherapy.
  • MAIN OUTCOME MEASURES: Histopathology, site of primary tumor, intratemporal location of regional spread along the facial nerve, degree of facial paralysis, and presence of residual disease.
  • In addition, one case of benign pleomorphic adenoma of the parotid gland that circumferentially involved an intratemporal segment of the facial nerve was reported.
  • Four patients had unresectable malignant disease, and two died despite multimodality therapy.
  • CONCLUSIONS: The facial nerve provides a route for the spread of neoplastic disease into the temporal bone, and perineural invasion is an important mechanism of invasion and motility of malignant disease.
  • Nonneurogenic intratemporal tumors of the facial nerve are a rare but significant cause of facial paralysis.
  • [MeSH-major] Carcinoma / pathology. Cranial Nerve Neoplasms / pathology. Facial Nerve / pathology. Parotid Neoplasms / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Child. Female. Gadolinium. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Radiopharmaceuticals. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621352.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


8. Boujaoude J: Role of endoscopic ultrasound in diagnosis and therapy of pancreatic adenocarcinoma. World J Gastroenterol; 2007 Jul 21;13(27):3662-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of endoscopic ultrasound in diagnosis and therapy of pancreatic adenocarcinoma.
  • Since its advent more than 20 years ago, endoscopic ultrasound (EUS) has undergone evolution from an experimental to a diagnostic instrument and is now established as a therapeutic tool for endoscopists.
  • Endoscopic ultrasound cannot accurately distinguish benign from malignant changes in the primary lesion or lymph node on imaging alone.
  • The curved linear array echoendoscope enables the visualization of a needle as it exits from the biopsy channel in the same plane of ultrasound imaging in real time.
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Autonomic Nerve Block / methods. Biopsy, Fine-Needle / methods. Catheter Ablation / methods. Celiac Plexus. Cholangiography / methods. Diagnosis, Differential. Drug Delivery Systems / methods. Humans. Neoplasm Staging / methods. Photochemotherapy / methods. Predictive Value of Tests. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659723.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  • [Other-IDs] NLM/ PMC4250635
  •  go-up   go-down


9. Stark AM, Buhl R, Hugo HH, Mehdorn HM: Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature. Acta Neurochir (Wien); 2001;143(4):357-63; discussion 363-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature.
  • BACKGROUND: Though Malignant peripheral nerve sheath tumours (MPNST) are a rare entity accounting for 5-10% of soft-tissue sarcomas they are an important differential diagnosis to benign tumours of the peripheral nervous system regarding treatment and prognosis.
  • Two patients suffered from Neurofibromatosis type 1.
  • All of these developed local recurrence with a mean disease free survival time of 10.6 months.
  • During follow up, three patients developed distant metastases located in the lung, liver and subcutaneous tissue.
  • Five out of eight patients died during follow-up with a mean survival time of 11.6 months after diagnosis.
  • Though mulitimodal therapy including surgical resection and adjuvant radiotherapy including brachytherapy is available, the prognosis remains dismal.
  • Modern clinical studies and the development of effective chemotherapy is needed in order to gain control of the disease.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / surgery. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / surgery. Thoracic Neoplasms / mortality. Thoracic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11437289.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 5
  •  go-up   go-down


10. Zhi K, Ren W, Zhou H, Wen Y, Zhang Y: Management of parapharyngeal-space tumors. J Oral Maxillofac Surg; 2009 Jun;67(6):1239-44
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All cases were evaluated with at least a computed tomography scan.
  • The most common class of lesion was salivary-gland neoplasm, accounting for 74 cases (45.68%).
  • Twenty patients with malignant disease underwent adjuvant chemotherapy and/or radiotherapy.
  • Two patients suffered local failure, and 4 patients developed distant metastasis during the observation period.
  • CONCLUSIONS: Surgery is the mainstay treatment for PPS tumors.
  • The most common approach was transcervical-transparotid for benign tumors.
  • [MeSH-minor] Adenoma, Pleomorphic / surgery. Adult. Biopsy, Fine-Needle. Carcinoma / secondary. Carcinoma / surgery. Chemotherapy, Adjuvant. Cranial Nerve Diseases / etiology. Female. Follow-Up Studies. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Neck Muscles / surgery. Neoplasm Recurrence, Local / pathology. Parotid Gland / surgery. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Salivary Gland Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Oral Maxillofac Surg. 2010 May;68(5):1209-11; author reply 1212 [20403530.001]
  • (PMID = 19446210.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Kaufman LM, Doroftei O: Optic glioma warranting treatment in children. Eye (Lond); 2006 Oct;20(10):1149-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic glioma warranting treatment in children.
  • PURPOSE: To describe cases of optic pathway glioma (OPG) warranting treatment in children.
  • Three of the patients were also ultimately diagnosed with neurofibromatosis type 1.
  • Six of the patients were treated with intravenous chemotherapy, with three patients requiring a second chemotherapy cycle.
  • One patient was successfully treated with an en-bloc optic nerve excision.
  • CONCLUSION: Although benign tumours, OPG can behave very aggressively in young children.
  • Both chemotherapy and en-bloc excision can be employed for treatment.
  • [MeSH-major] Optic Nerve Glioma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Disease Progression. Exophthalmos / etiology. Eye Enucleation. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neurofibromatosis 1 / complications. Neurofibromatosis 1 / diagnosis. Neurofibromatosis 1 / pathology. Neurofibromatosis 1 / therapy. Optic Nerve / pathology. Optic Nerve / surgery. Retrospective Studies. Treatment Outcome. Vision Disorders / etiology

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019413.001).
  • [ISSN] 0950-222X
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY 1792
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


12. Lehnhardt M, Daigeler A, Homann HH, Hauser J, Langer S, Steinsträsser L, Soimaru C, Puls A, Steinau HU: [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases]. Chirurg; 2009 Apr;80(4):341-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases].
  • [Transliterated title] Die Bedeutung von Referenzzentren in Diagnose und Therapie von Weichgewebssarkomen der Extremitäten. Auswertung von 603 Fällen.
  • Correct histopathologic diagnosis is essential for adequate treatment of soft tissue sarcomas.
  • The records of 603 patients with soft tissue tumors of the extremities were reviewed concerning mismatches in primary and definite diagnoses relating to entity, evaluation of primary or recurrent tumor specimens, and the diagnosing pathology institution.
  • In the eight most frequent sarcoma types, malignant peripheral nerve sheath tumors and leiomyosarcoma had the highest rates of false primary diagnosis, 78.4% and 74.2% of cases, respectively.
  • For optimal treatment of soft tissue sarcomas, we suggest obtaining expert second opinion to ensure adequate surgical therapy and precise indications for radiation and chemotherapy.
  • [MeSH-major] Cancer Care Facilities. Extremities / surgery. Hospitals, Special. Hospitals, University. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diagnostic Errors. Female. Germany. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / diagnosis. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Neoplasm Staging. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery. Radiotherapy, Adjuvant. Referral and Consultation. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):473-6 [11601130.001]
  • [Cites] Cancer Treat Res. 2004;120:43-63 [15217217.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):235-9 [16754344.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):514-7 [7605166.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):300-6 [15946590.001]
  • [Cites] Can J Surg. 1988 Nov;31(6):404-6 [3179848.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] Ann Diagn Pathol. 1999 Feb;3(1):48-61 [9990113.001]
  • [Cites] Curr Top Pathol. 1995;89:123-51 [7882706.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):451-62 [15509479.001]
  • [Cites] Pathol Res Pract. 1988 Nov;183(6):698-705 [2851775.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):77-86 [15188669.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):212-9 [10613171.001]
  • [Cites] Bull Cancer. 2001 Aug;88(8):765-73 [11578945.001]
  • [Cites] Curr Oncol Rep. 2006 Jul;8(4):305-9 [17254531.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):111-5 [11823981.001]
  • [Cites] Chirurg. 2007 Jan;78(1):62-4 [16786340.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):157-67 [11856592.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):237-46 [15056054.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Verh Dtsch Ges Pathol. 2006;90:59-72 [17867581.001]
  • [Cites] Cancer Treat Res. 1993;67:1-22 [8102867.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):329-35 [10989631.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):315-20 [1892759.001]
  • (PMID = 18523742.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Krampulz T, Hans VH, Oppel F, Dietrich U, Puchner MJ: Long-term relapse-free survival with supratentorial primitive neuroectodermal tumor in an adult: a case report. J Neurooncol; 2006 May;77(3):291-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: In adults, supratentorial primitive neuroectodermal tumor (sPNET) is a very rare undifferentiated embryoblastic neoplasm.
  • The patient was treated by CyVADIC chemotherapy and conventional radiation therapy (60 Gy).
  • CONCLUSIONS: Although the prognosis of sPNET is reported to be poor, a small fraction with a rather benign biological and clinical behavior exists.
  • The value of chemotherapy is an issue of continuous investigation.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Disease-Free Survival. Humans. Ki-67 Antigen / metabolism. Male. Receptor, Nerve Growth Factor / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Jan;41(1):56-63 [626943.001]
  • [Cites] Med Pediatr Oncol. 2002 Sep;39(3):190-4 [12210449.001]
  • [Cites] Br J Radiol. 2003 Jan;76(901):62-5 [12595327.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] Cancer. 1980 Mar 1;45(5):840-4 [7260835.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1027-35 [10694553.001]
  • [Cites] Pediatr Neurosurg. 1998 Oct;29(4):170-7 [9876245.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):268-73 [11452934.001]
  • [Cites] J Neurooncol. 1990 Aug;9(1):77-80 [2170592.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2 [10981749.001]
  • [Cites] Acta Oncol. 2003;42(1):55-61 [12665332.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):57-62 [11451203.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):142-8 [10391574.001]
  • [Cites] Surg Neurol. 1983 Jul;20(1):30-5 [6306852.001]
  • [Cites] Ann Neurol. 1996 Apr;39(4):481-9 [8619526.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):113-20 [12622449.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):905-9 [2033450.001]
  • [Cites] Br J Neurosurg. 1999 Feb;13(1):90-2 [10492697.001]
  • [Cites] Acta Cytol. 2000 Nov-Dec;44(6):1050-8 [11127734.001]
  • [Cites] J Neuropathol Exp Neurol. 1983 Jan;42(1):1-15 [6296325.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):951-7 [7607969.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):43-52 [12416545.001]
  • [Cites] J Neurooncol. 1998 Feb;36(3):259-67 [9524104.001]
  • [Cites] BMC Cancer. 2004 Jan 26;4:3 [14969593.001]
  • (PMID = 16528456.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptor, Nerve Growth Factor
  •  go-up   go-down


14. Rittinger O, Kranzinger M, Jones R, Jones N: Malignant astrocytoma arising 10 years after combined treatment of craniopharyngioma. J Pediatr Endocrinol Metab; 2003 Jan;16(1):97-101
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant astrocytoma arising 10 years after combined treatment of craniopharyngioma.
  • After surgery he underwent conventional radiation therapy with a total tumor dose of 55 Gy, and had hormonal support with DDAVP, thyroxine, and a variable dose of hydrocortisone.
  • Growth velocity declined slowly in the first 4 years, but improved later on again without GH therapy despite abnormal provocative tests.
  • At the age of 15 years he developed peripheral facial nerve palsy due to a malignant astrocytoma (WHO grade III/IV).
  • Repeated conventional radiation therapy with an additional stereotactic boost and chemotherapy could not prevent the fatal outcome.
  • This observation may temper the use of radiosurgery in benign intracranial tumors.
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Fatal Outcome. Hormones / blood. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Time Factors

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12585346.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hormones
  •  go-up   go-down


15. Koeller KK, Rushing EJ: From the archives of the AFIP: pilocytic astrocytoma: radiologic-pathologic correlation. Radiographics; 2004 Nov-Dec;24(6):1693-708
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilocytic astrocytoma is the most common pediatric central nervous system glial neoplasm and the most common pediatric cerebellar tumor.
  • This tumor has a noteworthy benign biologic behavior that translates into an extremely high survival rate-94% at 10 years-that is by far the best of any glial tumor.
  • The cerebellum, optic nerve and chiasm, and hypothalamic region are the most common locations, but the tumor can also be found in the cerebral hemisphere, ventricles, and spinal cord.
  • Surgical resection is the treatment of choice for all tumors, except for those involving the optic pathway and hypothalamic region, which may be treated with radiation therapy and chemotherapy.
  • Accurate interpretation of imaging studies plays an essential role in directing treatment of these tumors, particularly when they arise in the optic pathway of patients with neurofibromatosis type 1.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15537977.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 98
  •  go-up   go-down


16. Pelizzo MR, Piotto A, Bergamasco A, Rubello D, Casara D: [Parathyroid carcinoma. Therapeutic strategies derived from 20 years of experience]. Minerva Endocrinol; 2001 Mar;26(1):23-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parathyroid carcinoma. Therapeutic strategies derived from 20 years of experience].
  • We describe their clinical presentation, treatment and results obtained.
  • The symptoms at onset included: nephrolithiasis in 10 cases, osteoporosis in 4 (3 of which presented uremic syndromes), gastrointestinal symptoms (gastritis) in 1 case, a palpable cervical mass in 1 patient and recurrent nerve palsy in one case suffering from familial IPT.
  • RESULTS: Parathyroid carcinoma was correctly diagnosed during the first operation in 14 cases (this diagnosis was suspected in 10 cases following intraoperative frozen session), whereas the first diagnosis was of benign disease in 3 patients.
  • Two patients underwent radiotherapy after surgery and one received chemotherapy.
  • CONCLUSIONS: In conclusion, high blood levels of calcium and PTH, a palpable mass at the neck, with recurrent nerve paralysis, aspects of local invasiveness should alert the surgeon and guide him towards surgery that includes resection of the parathyroid en bloc with the adjacent structures, although there is no proof that a more extensive surgery is correlated with a more favourable prognosis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Gastritis / etiology. Humans. Hypercalcemia / etiology. Hyperparathyroidism / etiology. Italy / epidemiology. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Osteoporosis / etiology. Reoperation. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Urinary Calculi / etiology. Vocal Cord Paralysis / etiology

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11323564.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 15
  •  go-up   go-down


17. Obaid MA, Yusuf A: Surgical management of epithelial parotid tumours. J Coll Physicians Surg Pak; 2004 Jul;14(7):394-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the clinicopathological presentation and treatment options in epithelial parotid tumours with emphasis on surgery.
  • Clinical presentation, preoperative investigations, operative procedure, histopathology report, postoperative complications and further management were recorded.
  • Majority of tumours were benign, only two were recurrent.
  • Parotid pleomorphic Adenoma (PPA) was the commonest benign tumour, others being Warthin's tumour and monomorphic adenoma.
  • Except for one child, rest of the 13 patients received postoperative radiotherapy and one patient of lymphoepithelioma received chemotherapy in addition.
  • CONCLUSION: Benign and malignant epithelial parotid tumours can be diagnosed by their clinical presentation supplemented with FNAC.
  • Facial nerve can be saved in total conservative parotidectomy for benign tumour in deep lobe and early malignant tumour.
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Glandular and Epithelial / mortality. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / surgery. Postoperative Complications. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15279739.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


18. Christensen NR, Charabi S, Johansen LS, Rygaard J, Balle VH, Tos M, Thomsen J: Effect of photodynamic therapy on a heterotransplanted human parotid tumor. Auris Nasus Larynx; 2000 Jul;27(3):241-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of photodynamic therapy on a heterotransplanted human parotid tumor.
  • To evaluate the effect of photodynamic therapy on human parotid tumors we used tumor specimens obtained from parotid surgery on a consecutive group of patients.
  • We re-implanted this tumor on ten mice bilaterally, and treated the tumors with photodynamic therapy (PDT), resulting in a mean depth of tumor necrosis of 5.4 mm (1-10 mm).
  • In three cases we found vital tumor cells in the periphery of the tumor after treatment, with several new blood vessels in the surrounding tissue, indicating a great potential for neo-angiogenesis in this tumor.
  • In order to evaluate the possible nerve damage subsequent to the photodynamic therapy, the ischiadic nerve in 24 lower limbs of nude mice were investigated.
  • In one case only the macroscopical and histological investigation revealed signs of nerve damage.
  • The current study demonstrates that the nude mice implantation model is excellent to investigate growth in both malignant and benign parotid tumors, and to test new therapeutic modalities.
  • Photodynamic therapy seems to have a possible role in the future management of the malignant lesions of the parotid gland, in cases where radical surgery for some reason is not achievable.
  • [MeSH-major] Neoplasm Transplantation. Parotid Neoplasms / drug therapy. Photochemotherapy. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10808112.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down


19. Schoemaker MJ, Swerdlow AJ, Auvinen A, Christensen HC, Feychting M, Johansen C, Klaeboe L, Lönn S, Salminen T, Tynes T: Medical history, cigarette smoking and risk of acoustic neuroma: an international case-control study. Int J Cancer; 2007 Jan 1;120(1):103-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acoustic neuroma (vestibular schwannoma) is a benign tumor of the vestibulocochlear nerve.
  • Risk was not associated with a history of allergic disease, past head injury, past diagnosis of a neoplasm or birth characteristics, but was significantly raised for past diagnosis of epilepsy (OR = 2.5, 95% CI: 1.3-4.9).
  • The raised risk in relation to past diagnosis of epilepsy might be a surveillance artefact or imply that epilepsy and/or antiepileptic medication use predispose to acoustic neuroma.
  • [MeSH-minor] Adolescent. Adult. Aged. Asthma / complications. Case-Control Studies. Eczema / complications. Epilepsy / complications. Epilepsy / drug therapy. Female. Humans. Male. Medical History Taking. Middle Aged. Risk Factors






Advertisement